Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Chris Parker,Robert Coleman,Oliver Sartor,Nicholas J. Vogelzang,David Bottomley,Daniel Heinrich,Svein Inge Helle,Joe M. O’Sullivan,Sophie D. Fossa,A. Chodacki,Paweł Wiechno,John P Logue,Mihalj Seke,Anders Widmark,Dag Clement Johannessen,Peter Hoskin,Nicholas D. James,Arne Solberg,Isabel Syndikus,J. Kliment,Steffen Wedel,Sibylle Boehmer,Marcos F. DallOglio,Lars Franzén,Øyvind S. Bruland,Oana Petrenciuc,K. Staudacher,Rui Li,Sten Nilsson

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

2017

Background: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patient ...

Keywords:

Placebo
Urology
Pathology
Prostate cancer
Castration
Radium-223 Dichloride
Medicine
Radium-223
castration resistant
long term safety
overall survival
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations